
    
      The study will have a Run-in portion and an Expansion portion. The Run-in portion will be
      used to evaluate the safety profile of the PEGCISGEM and PEGCISGEMATEZO treatments prior to
      evaluating the efficacy and safety of PEGCISGEM and PEGCISGEMATEZO treatments compared with
      CISGEM treatment in the Expansion portion of the study. Treatment in both portions of the
      study will continue until death, withdrawal of consent from the study, disease progression,
      or unacceptable toxicity.
    
  